Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

325 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Novel WRN Helicase Inhibitors Selectively Target Microsatellite Unstable Cancer Cells.
Picco G, Rao Y, Al Saedi A, Lee Y, Vieira SF, Bhosle S, May K, Herranz-Ors C, Walker SJ, Shenje R, Dincer C, Gibson F, Banerjee R, Hewitson Z, Werner T, Cottom JE, Peng Y, Deng N, Landis P, Conticelli D, McCarten K, Bush J, Sharma M, Lightfoot H, House D, Milford E, Grant EK, Glogowski MP, Wagner CD, Bantscheff M, Rutkowska-Klute A, Network Uk Group CM, Zappacosta F, Pettinger J, Barthorpe S, Eberl HC, Jones BT, Schneck JL, Murphy DJ, Voest EE, Taygerly JP, DeMartino MP, Coelho MA, Houseley J, Sharma G, Schwartz BJ, Garnett MJ. Picco G, et al. Among authors: voest ee. Cancer Discov. 2024 Apr 9. doi: 10.1158/2159-8290.CD-24-0052. Online ahead of print. Cancer Discov. 2024. PMID: 38587317
Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy.
Picco G, Cattaneo CM, van Vliet EJ, Crisafulli G, Rospo G, Consonni S, Vieira SF, Rodríguez IS, Cancelliere C, Banerjee R, Schipper LJ, Oddo D, Dijkstra KK, Cinatl J, Michaelis M, Yang F, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Arena S, Voest EE, Bardelli A, Garnett MJ; Cell Model Network UK Group. Picco G, et al. Among authors: voest ee. Cancer Discov. 2021 Aug;11(8):1923-1937. doi: 10.1158/2159-8290.CD-20-1508. Epub 2021 Apr 9. Cancer Discov. 2021. PMID: 33837064 Free article.
Can Drug Repurposing Accelerate Precision Oncology?
Schipper LJ, Zeverijn LJ, Garnett MJ, Voest EE. Schipper LJ, et al. Among authors: voest ee. Cancer Discov. 2022 Jul 6;12(7):1634-1641. doi: 10.1158/2159-8290.CD-21-0612. Cancer Discov. 2022. PMID: 35642948 Review.
Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment.
Devriese LA, Witteveen PO, Marchetti S, Mergui-Roelvink M, Reyderman L, Wanders J, Jenner A, Edwards G, Beijnen JH, Voest EE, Schellens JH. Devriese LA, et al. Among authors: voest ee. Cancer Chemother Pharmacol. 2012 Dec;70(6):823-32. doi: 10.1007/s00280-012-1976-x. Epub 2012 Sep 26. Cancer Chemother Pharmacol. 2012. PMID: 23010853 Clinical Trial.
Author Correction: The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology.
Tamborero D, Dienstmann R, Rachid MH, Boekel J, Lopez-Fernandez A, Jonsson M, Razzak A, Braña I, De Petris L, Yachnin J, Baird RD, Loriot Y, Massard C, Martin-Romano P, Opdam F, Schlenk RF, Vernieri C, Masucci M, Villalobos X, Chavarria E; Cancer Core Europe consortium; Balmaña J, Apolone G, Caldas C, Bergh J, Ernberg I, Fröhling S, Garralda E, Karlsson C, Tabernero J, Voest E, Rodon J, Lehtiö J. Tamborero D, et al. Nat Cancer. 2022 May;3(5):649. doi: 10.1038/s43018-022-00378-x. Nat Cancer. 2022. PMID: 35449310 Free PMC article. No abstract available.
325 results